Exicure (XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, reported financial results for 2Q 2019 & an update on corporate progress.
2Q 2019 Progress & Recent Developments
Announced important preclinical data supporting development of SNA technology in the central nervous system (CNS)
Expanded Board with experienced biotechnology leaders
AST-008 Phase 1b/2 clinical trial continues to progress—AST-008 is an SNA consisting of toll-like receptor 9 agonists designed for immuno-oncology applications.
Enhanced Financial Resources
• Up-listed from the OTC to the Nasdaq Capital Market.
• Closed oversubscribed underwritten public offering of 31,625,000 shares of common stock
• Insider participation of approximately $2.6 M
“The first half of 2019 continued to bring advancements across our pipeline,” said Dr. David Giljohann, Exicure’s chief executive officer. “We are extremely pleased with the strong progress in both our neurology and oncology franchises, while we simultaneously strengthened our board leadership and balance sheet. Our non-human primate data confirmed our enthusiasm for neurological applications of our SNA platform. Our recent $63.3 million public offering, which closed on August 2, 2019 provides the financial resources to advance these opportunities,” he added.